Tae‐Yong Kim

Seoul National University — South Korea

Medicine · Health Sciences

33h-index3.5kcitations198works2.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Gastric Cancer Management and Outcomes(44), HER2/EGFR in Cancer Research(32), Breast Cancer Treatment Studies(24), Cholangiocarcinoma and Gallbladder Cancer Studies(24), Pancreatic and Hepatic Oncology Research(20)

Publications198 total

Fadraciclib, a CDK2/CDK9 inhibitor, shows efficacy in biliary tract cancer and synergistic potential with olaparib and JQ1 based on MCL1 expression
Cell Communication and Signaling·2025· 1 citedOpen Access
Longitudinal trajectory of menopausal symptoms in premenopausal women throughout adjuvant chemotherapy: a two-stage analytical approach
Supportive Care in Cancer·2025
Targeting Riboflavin Kinase Induces Ferroptosis and Apoptosis in Triple-Negative Breast Cancer
2025Open Access
Multicenter single-arm phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab
Journal of Hepatology·2025· 8 cited
Therapeutic potential of BOLD-100, a GRP78 inhibitor, enhanced by ATR inhibition in pancreatic ductal adenocarcinoma
Cell Communication and Signaling·2025· 4 citedOpen Access
Phase III of oral paclitaxel (DHP107) vs intravenous paclitaxel in HER2-negative recurrent or metastatic breast cancer (mBC): Primary analysis of a multinational optimal trial (NCT03315364).
Journal of Clinical Oncology·2025· 1 cited
Abstract 1497: PERK as a biomarker to optimize therapy of GRP78 inhibitor, BOLD-100, in gastric cancer
Cancer Research·2025
Data from ILUSTRO: Phase 2 Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
2024Open Access
Supplementary Data 1 from ILUSTRO: Phase 2 Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
2024Open Access
Supplementary Data 1 from ILUSTRO: Phase 2 Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
2024Open Access
Differential effects of desvenlafaxine on hot flashes in women with breast cancer taking tamoxifen: a randomized controlled trial
npj Breast Cancer·2024· 2 citedOpen Access
Differences in severity of chemotherapy-induced nausea and vomiting between neoadjuvant and adjuvant chemotherapy in patients with breast cancer: analysis of data from two prospective observational studies
Supportive Care in Cancer·2024
Laparoscopic Conversion Surgery After Three Years of Palliative Chemotherapy for Unresectable Advanced Gastric Cancer
Journal of surgical innovation and education (Online)·2024Open Access
Treatment Outcome and Safety of Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small Cell Lung Cancer
2024
Abstract 5711: Anti-tumor effects of fadraciclib, CDK2/9 inhibitor, in biliary tract cancer
Cancer Research·2024
Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis
Journal of Liver Cancer·2024· 10 citedOpen Access
Blood Pb levels are associated with prostate cancer prevalence among general adult males: Linking National Cancer Registry (2002–2017) and KNHANES (2008–2017) databases of Korea
International Journal of Hygiene and Environmental Health·2024· 11 cited
Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trial
European Journal of Cancer·2023· 4 cited
EP12.01-27 Final Report on Real World Effectiveness of Sequential Afatinib and Osimertinib in EGFR Positive Advanced Non-small Cell Lung Cancer
Journal of Thoracic Oncology·2023Open Access
Supplementary Data 1 from ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2–Positive Gastric or Gastroesophageal Junction Adenocarcinoma
2023Open Access
page 1 of 10Next →

Frequent Co-authors

Seock‐Ah Im(37), Kyung-Hun Lee(26), Do‐Youn Oh(25), Sae‐Won Han(21), Yung‐Jue Bang(19), Tae‐You Kim(7), Wonshik Han(7), Hyeong‐Gon Moon(7), Dong‐Young Noh(7), Tae‐You Kim(6), Kyung-Hun Lee(6), Jin Won Kim(6), Jee Hyun Kim(6), In Ae Park(6), Ahrum Min(5), Han Suk Ryu(5), Ji‐Won Kim(4), Han‐Byoel Lee(4), Hee Jun Kim(3), Yeon Hee Park(3)